M&A Deal Summary

Theriva Biologics Acquires VCN

On December 14, 2021, Theriva Biologics acquired life science company VCN from Grifols for 75M USD

Acquisition Highlights
  • This is Theriva Biologics’ 1st transaction in the Life Science sector.
  • This is Theriva Biologics’ largest (disclosed) transaction.
  • This is Theriva Biologics’ 1st transaction in Spain.

M&A Deal Summary
Date 2021-12-14
Target VCN
Sector Life Science
Buyer(s) Theriva Biologics
Sellers(s) Grifols
Deal Type Divestiture
Deal Value 75M USD

Target

VCN

Barcelona, Spain
VCN is a clinical-stage biotech company focused on developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal (IVit) delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. VCN is based in Barcelona, Spain.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Theriva Biologics

Rockville, Maryland, United States
Category Company
Sector Life Science
Employees22
Revenue 21M USD (2023)
DESCRIPTION

Theriva Biologics is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. Theriva Biologics is based in Rockville, Maryland.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Spain) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Grifols

Barcelona, Spain
Category Company
Founded 1909
Sector Healthcare Services
Employees23,000
Revenue 6.6B EUR (2023)
DESCRIPTION

Grifols is a global healthcare company and biopharmaceutical manufacturer. Grifols was founded in 1909 and is based in Barcelona, Spain.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (Spain) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-17 Biotest

Dreieich, Germany

Biotest specializes in innovative hematology and clinical immunology solutions. The company develops, produces and markets biological medicinal products with applications in hematology, clinical immunology and intensive care. It's current portfolio includes 12 different products with a global commercial footprint in more than 90 countries. Biotest was founded in 1946 and is based in Dreieich, Germany.

Buy €1.6B
Mergr

Product

Company

Legal